PLANTATION, Fla., June 30, 2008 (PRIME NEWSWIRE) -- Goodwin Biotechnology Inc. (GBI) disclosed today that it has begun process development toward AREVA's lead-212 initiative to treat cancer. As part of this agreement, GBI will manufacture a new conjugated drug that will be radiolabeled by the NCI with lead-212. AREVA's long-term expertise in the nuclear industry allowed for the production of this radioisotope previously considered a scarce resource.

Said GBI CEO Stephanie Finnegan, "We are proud to have been chosen for this project, which could revolutionize radiopharmaceuticals."

About Goodwin Biotechnology Inc.

GBI is one of the earliest contract manufacturing organizations (CMOs), established in 1992. GBI specializes in process development and cGMP compliant mammalian cell culture manufacturing of bio-therapeutics for pre-clinical studies through Phase III clinical trials. GBI's clients include small to midsized biotech companies throughout North America and Europe, universities, renowned cancer research institutes and various branches of the U.S. government. GBI offers its clients the experience of an established US Contract Manufacturing Organization and provides services in a fully integrated offering, including process development, cell banking, GMP manufacture, conjugation, vialing, and distribution to the clinical trial sites.

The Goodwin Biotechnology Inc. logo is available at

About AREVA Inc.

With manufacturing facilities in 43 countries and a sales network in more than 100, AREVA offers customers reliable technological solutions for CO2-free power generation and electricity transmission and distribution. We are the world leader in nuclear power and the only company to cover all industrial activities in this field. Our 65,000 employees are committed to continuous improvement on a daily basis, making sustainable development the focal point of the group's industrial strategy. AREVA's businesses help meet the 21st century's greatest challenges: making energy available to all, protecting the planet, and acting responsibly towards future generations.

The AREVA Inc. logo is available at

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

Patrick Bourdet 
(301) 841-1600

4800 Hampden Lane, Suite 1100
Bethesda, Maryland 20814

Goodwin Biotechnology Inc.
Stephanie Finnegan, CEO 
(954) 327-9606

1850 NW 69 Avenue
Plantation, Florida 33313